Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP14 - Targeted Therapy - Clinically Focused
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
-
+
FP14.07 - Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
00:00 - 00:00 | Presenter: Julia K Rotow
- Abstract
Loading...
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P14.21 - Baseline Derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Clinical Outcomes to First-Line Pembrolizumab in NSCLC with High PD-L1 (≥50%)
00:00 - 00:00 | Presenter: Joao Victor M. Alessi
- Abstract
Loading... -
+
P14.26 - Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status
00:00 - 00:00 | Presenter: Biagio Ricciuti
- Abstract
Loading...
-
+
P16 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Translational)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P16.07 - Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON)
00:00 - 00:00 | Presenter: Benjamin Besse
- Abstract
Loading...
-
+
P33 - Pathology - Immunotherapy Biomarker
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
P33.04 - Programmed Death-Ligand 1 (PD-L1) Changes in Non-Small-Cell Lung Cancer (NSCLC): Clinical, Pathologic, and Genomic Correlates
00:00 - 00:00 | Presenter: Stephanie L. Alden
- Abstract
Loading...
-
+
P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P77.01 - Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC
00:00 - 00:00 | Presenter: John Wrangle
- Abstract
Loading...
-
+
OA07 - Immuno-biology and Novel Immunotherapeutics from Bench to Bed
- 10:30 - 11:30
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
OA07.08 - HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
11:05 - 11:10 | Presenter: Benjamin Besse
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.06 - Discussant
14:30 - 14:35 | Presenter: Mark M. Awad
- Abstract
No abstract available for this presentation
